Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on MTC’s Substack. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $483.46 as of March 16th. ISRG’s trailing and forward P/E were 59.99 and 47.39 respectively according to Yahoo Finance.
Master Video/Shutterstock.com
Intuitive Surgical, Inc. (ISRG) stands as a defining force in modern medical technology, having pioneered and scaled robotic surgery into a dominant global platform with approximately 70% market share, a 12,000-system installed base, and a business model generating nearly 85% recurring revenue. The company’s leadership is anchored in its da Vinci ecosystem, including the recently launched da Vinci 5, which delivers step-change improvements in computing power and introduces force feedback technology, alongside established systems like Xi, X, and SP that serve a broad range of surgical specialties.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Complementing this portfolio is the Ion platform, expanding Intuitive Surgical’s reach into minimally invasive diagnostics, particularly lung cancer detection. Its razor-and-blade model drives durable economics, with high-margin instruments and accessories contributing the majority of revenue and creating long-term, non-discretionary demand tied to procedure volumes, which exceeded 3 million annually.
The company operates in a robotic surgery market expected to grow from roughly $16 billion in 2026 to over $50 billion by 2035, supported by increasing adoption across general surgery and international markets, where penetration remains relatively low. While Intuitive Surgical has already achieved meaningful penetration in urology and gynecology, significant whitespace remains, particularly in general surgery, representing a substantial volume expansion opportunity.
Its competitive position is reinforced by high switching costs, deep surgeon training integration, a vast patent portfolio, and a powerful data moat built on millions of procedures, enabling continuous innovation and AI-driven advancements. Although competition from players like Medtronic and Johnson & Johnson is intensifying, Intuitive Surgical’s entrenched ecosystem, scale advantages, and proven clinical outcomes position it to sustain leadership and capture a disproportionate share of this expanding market, offering a compelling long-term growth and rerating opportunity.
